EMG
GNMX

ETF Managers Group’s Aevi Genomic Medicine Inc GNMX Stock Holding History

ETF Managers Group’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-58,967
Closed -$74K – 539
2017
Q3 		$74K Buy
58,967
+3,657
+7% +$4.67K 0.01% 155
2017
Q2 		$74K Buy
+55,310
New +$79.9K 0.01% 209

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

ETF Managers Group's GNMX Position: Q4 2017 in Review

ETF Managers Group sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2017, closing a stake of 58,967 shares — an estimated $74K sold.

ETF Managers Group first reported a position in GNMX in Q2 2017 and held it in 2 quarters. The position peaked at $74K in Q3 2017. 45 funds tracked by Wall St. Rank hold GNMX as of Q4 2017.

  • ETF Managers Group reported no remaining Aevi Genomic Medicine Inc position as of Q4 2017 after selling out during the quarter.
  • ETF Managers Group sold 58,967 Aevi Genomic Medicine Inc shares in Q4 2017, an estimated $74K.
  • ETF Managers Group first reported a position in Aevi Genomic Medicine Inc in Q2 2017 and held it in 2 quarters.
  • ETF Managers Group's Aevi Genomic Medicine Inc position peaked at $74K in Q3 2017.
  • 45 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2017.

Based on ETF Managers Group's 13F filing for Q4 2017, filed 14 Feb 2018.